BioXcel Therapeutics (BTAI) Income from Continuing Operations (2017 - 2026)

BioXcel Therapeutics' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 14210000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 2.87% year-over-year to 14210000.0; the TTM figure through Mar 2026 stood at 59041000.0 (up 1.35% YoY), while the FY2025 annual figure was 66379000.0, up 74.15% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 14210000.0, down from 7063000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 7063000.0 in Q4 2025, with the low at 169781000.0 in Q4 2022.
• The 5-year median for Income from Continuing Operations is 20991000.0 (2023), against an average of 43101588.24.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 549.88% in 2022, then jumped 87.64% in 2023.
• BioXcel Therapeutics' Income from Continuing Operations stood at 169781000.0 in 2022, then surged by 87.64% to 20991000.0 in 2023, then surged by 65.5% to 7241000.0 in 2024, then increased by 2.46% to 7063000.0 in 2025, then slumped by 101.19% to 14210000.0 in 2026.
• Business Quant data shows BTAI's Income from Continuing Operations at 14210000.0 in Q1 2026, 7063000.0 in Q4 2025, and 17924000.0 in Q3 2025.